SiBone (NASDAQ:SIBN) Director Timothy Davis, Jr. Sells 3,500 Shares

SiBone (NASDAQ:SIBN) Director Timothy Davis, Jr. sold 3,500 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $14.14, for a total transaction of $49,490.00. Following the completion of the transaction, the director owned 65,722 shares in the company, valued at $929,309.08. The trade was a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

SiBone Trading Down 1.6%

NASDAQ SIBN traded down $0.23 during mid-day trading on Monday, hitting $13.87. The company’s stock had a trading volume of 619,291 shares, compared to its average volume of 658,591. SiBone has a 52-week low of $11.48 and a 52-week high of $21.89. The stock’s fifty day simple moving average is $13.53 and its two-hundred day simple moving average is $16.06. The company has a debt-to-equity ratio of 0.20, a current ratio of 9.99 and a quick ratio of 8.34. The firm has a market capitalization of $615.13 million, a P/E ratio of -35.56 and a beta of 0.70.

SiBone (NASDAQ:SIBN) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.10) EPS for the quarter, beating the consensus estimate of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. Research analysts expect that SiBone will post -0.44 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research firms have recently issued reports on SIBN. TD Cowen dropped their price objective on shares of SiBone from $22.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, May 12th. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, April 18th. Finally, Truist Financial reiterated a “buy” rating and set a $18.00 price objective (down from $20.00) on shares of SiBone in a research note on Tuesday, May 12th. Six research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, SiBone presently has a consensus rating of “Moderate Buy” and a consensus target price of $23.00.

Institutional Trading of SiBone

A number of hedge funds and other institutional investors have recently made changes to their positions in SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in shares of SiBone by 4.5% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock worth $343,000 after buying an additional 1,053 shares during the last quarter. Dynamic Technology Lab Private Ltd bought a new stake in shares of SiBone in the first quarter worth $225,000. Goldman Sachs Group Inc. increased its stake in shares of SiBone by 28.4% in the first quarter. Goldman Sachs Group Inc. now owns 379,757 shares of the company’s stock worth $5,328,000 after buying an additional 83,919 shares during the last quarter. Jane Street Group LLC bought a new stake in shares of SiBone in the first quarter worth $1,818,000. Finally, Legal & General Group Plc increased its stake in shares of SiBone by 16.1% in the second quarter. Legal & General Group Plc now owns 42,403 shares of the company’s stock worth $798,000 after buying an additional 5,888 shares during the last quarter. Institutional investors own 98.11% of the company’s stock.

SiBone Company Profile

Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.

FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.